Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Experts discuss how cancer treatment and survivorship can be made more equitable and affordable through advocacy, outreach, and effective communication tools. Beyond Cancer: Caring for Young ...

After hours: March 17 at 7:55:50 p.m. EDT ...

After hours: March 21 at 7:08:34 PM EDT Loading Chart for GLBS ...

Mar. 20, 2025 — Using CRISPR-based engineering methods to prompt stem cells to organize into embryo-like structures, scientists were able to create 'programmable' ...